Physician profile
Joseph Reddick
NPI 1750521936
$761.59
in general payments reported to CMS, 2019-2025
16 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.85 · 2022: $39.46 · 2023: $137 · 2024: $187 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $700.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $92.42 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $89.96 | 2025 | |
| Pfizer INC. | $85.86 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.01 | 2021-2025 | Jardiance |
| Amgen INC. | $68.30 | 2022-2023 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $63.44 | 2024-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $52.76 | 2023-2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $51.22 | 2025 | Korlym |
| Antares Pharma, INC. | $37.83 | 2025 | Xyosted |
| Merck Sharp & Dohme LLC | $34.49 | 2023-2025 | Capvaxive, Gardasil 9, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $29.68 | 2023-2025 | |
| Inspire Medical Systems, INC. | $21.45 | 2024 | Inspire |
| Esperion Therapeutics, INC. | $19.45 | 2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $14.37 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $13.60 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $12.75 | 2023 | Jardiance, Emgality |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Reddick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.